SCHEMBL17447266

SCHEMBL17447266

C=NOCc1ccc(C)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 10/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
IDO1 P14902 3/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
TDP1 Q9NUW8 2/20 0.38
KMT2A Q03164 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HPGD P15428 2/20 0.36
KDM4A O75164 1/20 0.36
KDM5A P29375 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17448775 0.81 ALDH1A1 (0.39) KDM4ELMNAMAPTSMN1; SMN2L3MBTL1
SCHEMBL16815030 0.81 IDO1 (0.58) KDM4ELMNAMAPTIDO1L3MBTL1
SCHEMBL12016053 0.77 IDO1 (0.42) KDM4EMAPTSMN1; SMN2IDO1L3MBTL1
SCHEMBL12960527 0.76 IDO1 (0.43) KDM4ELMNAMAPTSMN1; SMN2IDO1
SCHEMBL25394603 0.76 IDO1 (0.66) IDO1KDM4AKDM5AKDM2BKDM4C
SCHEMBL18213801 0.73 IDO1 (0.43) KDM4ELMNAMAPTSMN1; SMN2IDO1
SCHEMBL3084239 0.72 HPGD (0.38) LMNAMAPTSMN1; SMN2IDO1L3MBTL1
SCHEMBL13932525 0.72 AMY1A (0.42) LMNAMAPTSMN1; SMN2IDO1L3MBTL1
SCHEMBL2355598 0.72 TAAR1 (0.40) LMNAMAPTIDO1L3MBTL1TDP1
SCHEMBL12929384 0.71 IDO1 (0.38) KDM4ELMNAMAPTSMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION UNIV CASE WESTERN RESERVE (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION CHAT, PMP22, MAG KDM4E 1491/4885LMNA 1763/4885MAPT 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.